Difficulties defining the role of high-dose chemotherapy in the management of breast cancer.
作者信息
Markman M
出版信息
J Cancer Res Clin Oncol. 1995;121(11):631-2. doi: 10.1007/BF01218520.
Abstract
摘要
相似文献
1
Difficulties defining the role of high-dose chemotherapy in the management of breast cancer.界定高剂量化疗在乳腺癌治疗中作用的困难。
J Cancer Res Clin Oncol. 1995;121(11):631-2. doi: 10.1007/BF01218520.
2
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.基因表达谱分析和扩展免疫组织化学检测在乳腺癌管理中指导辅助化疗的应用：系统评价和成本效益分析。
Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440.
3
Cost-utility analyses of drug therapies in breast cancer: a systematic review.乳腺癌药物治疗的成本效用分析：一项系统综述
Breast Cancer Res Treat. 2016 Oct;159(3):407-24. doi: 10.1007/s10549-016-3924-7. Epub 2016 Aug 30.
4
Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.转移性乳腺癌细胞毒性和靶向治疗的成本效益：批判性和系统性综述。
Pharmacoeconomics. 2010;28(8):629-47. doi: 10.2165/11535560-000000000-00000.
5
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.密集化疗治疗非转移性乳腺癌：随机对照试验的系统评价和荟萃分析。
J Natl Cancer Inst. 2010 Dec 15;102(24):1845-54. doi: 10.1093/jnci/djq409. Epub 2010 Nov 23.
6
Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.对照组治疗对早期乳腺癌密集化疗获益的影响：系统评价和荟萃分析。
Breast Cancer Res Treat. 2018 Jun;169(3):413-425. doi: 10.1007/s10549-018-4710-5. Epub 2018 Feb 8.
7
High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.大剂量化疗及自体骨髓或干细胞移植与传统化疗治疗早期预后不良乳腺癌女性的对比研究
Cochrane Database Syst Rev. 2016 May 20;2016(5):CD003139. doi: 10.1002/14651858.CD003139.pub3.
8
Combination versus sequential single agent chemotherapy for metastatic breast cancer.转移性乳腺癌的联合化疗与序贯单药化疗对比研究
Cochrane Database Syst Rev. 2013 Dec 18;2013(12):CD008792. doi: 10.1002/14651858.CD008792.pub2.
9
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.西妥昔单抗（技术评估报告第176号综述）和帕尼单抗（技术评估报告第240号部分综述）用于既往未治疗的转移性结直肠癌的临床疗效和成本效果：一项系统评价与经济学评估
Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380.
10
Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer.成年癌症患者在家中与在医院或社区环境中接受静脉抗癌治疗的情况。
Cochrane Database Syst Rev. 2025 Apr 22;4(4):CD014861. doi: 10.1002/14651858.CD014861.pub2.
本文引用的文献
1
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.大剂量化疗及自体骨髓支持用于高危原发性乳腺癌标准剂量辅助治疗后的巩固治疗
J Clin Oncol. 1993 Jun;11(6):1132-43. doi: 10.1200/JCO.1993.11.6.1132.
2
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.美国临床肿瘤学会。造血集落刺激因子使用建议：循证临床实践指南。
J Clin Oncol. 1994 Nov;12(11):2471-508. doi: 10.1200/JCO.1994.12.11.2471.
3
The importance of dose intensity in chemotherapy of metastatic breast cancer.剂量强度在转移性乳腺癌化疗中的重要性。
J Clin Oncol. 1984 Nov;2(11):1281-8. doi: 10.1200/JCO.1984.2.11.1281.
4
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
J Clin Oncol. 1988 Sep;6(9):1368-76. doi: 10.1200/JCO.1988.6.9.1368.
5
More is better.
J Clin Oncol. 1988 Sep;6(9):1365-7. doi: 10.1200/JCO.1988.6.9.1365.
6
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.顺铂-环磷酰胺与卡铂-环磷酰胺治疗晚期卵巢癌的疗效比较：加拿大国家癌症研究所临床试验组的一项随机III期研究
J Clin Oncol. 1992 May;10(5):718-26. doi: 10.1200/JCO.1992.10.5.718.
7
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.卡铂联合环磷酰胺对比顺铂联合环磷酰胺的治疗指数提高：西南肿瘤协作组关于 III 期和 IV 期卵巢癌 III 期随机试验的最终报告
J Clin Oncol. 1992 May;10(5):706-17. doi: 10.1200/JCO.1992.10.5.706.
8
Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.非格司亭（G-CSF）动员的外周血祖细胞对大剂量化疗后血小板恢复的影响。
Lancet. 1992 Mar 14;339(8794):640-4. doi: 10.1016/0140-6736(92)90795-5.
Zotero 插件